Despite decades of cardiovascular medicine advances, roughly one in eight hypertensive patients continues experiencing elevated blood pressure even when prescribed optimal doses of three different antihypertensive medications from distinct drug classes. This persistent elevation, termed resistant hypertension, represents a critical blind spot in modern cardiology that significantly amplifies stroke, heart failure, and kidney disease risks compared to controlled hypertension cases.
The JAMA review consolidates evidence showing resistant hypertension prevalence ranges from 5% to 30% depending on population studied, with true resistance occurring in approximately 12% after accounting for medication adherence issues and white-coat syndrome. The condition often involves aldosterone excess, sleep apnea, or chronic kidney disease as underlying drivers. Fourth-line treatments including spironolactone, renal denervation procedures, and newer approaches like endothelin receptor antagonists show promise in clinical trials.
This comprehensive analysis arrives as healthcare systems grapple with suboptimal hypertension control rates nationwide. While resistant hypertension represents a relatively small subset of the 116 million Americans with high blood pressure, these patients consume disproportionate healthcare resources and face substantially elevated cardiovascular mortality. The review's emphasis on systematic evaluation protocols and emerging interventional approaches suggests the field is moving beyond simply adding more medications. However, the persistent challenge highlights fundamental gaps in understanding individual blood pressure regulation mechanisms. For health-conscious adults, this underscores the critical importance of lifestyle interventions—particularly sodium reduction, weight management, and sleep optimization—as foundational elements that may prevent progression to treatment-resistant states.